These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 32720627)
1. [Lipid-Lowering Therapy for Primary Cardiovascular Prevention in Older Adults. Consensus Statement of the Russian Association of Gerontologists and Geriatricians, National Society on Atherosclerosis, Russian Society of Cardiology, Association of Clinical Pharmacologists]. Kotovskaya YV; Tkacheva ON; Sergienko IV Kardiologiia; 2020 Jul; 60(6):1037. PubMed ID: 32720627 [TBL] [Abstract][Full Text] [Related]
2. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice. Bruckert E; Ferrières J Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429 [TBL] [Abstract][Full Text] [Related]
3. A Critical Review of the Consensus Statement from the European Atherosclerosis Society Consensus Panel 2017. Okuyama H; Hamazaki T; Hama R; Ogushi Y; Kobayashi T; Ohara N; Uchino H Pharmacology; 2018; 101(3-4):184-218. PubMed ID: 29353277 [TBL] [Abstract][Full Text] [Related]
5. South African dyslipidaemia guideline consensus statement: 2018 update A joint statement from the South African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA). Klug E; Raal FJ; Marais AD; Smuts CM; Schamroth C; Jankelow D; Blom DJ; Webb DA S Afr Med J; 2018 Oct; 108(11b):973-1000. PubMed ID: 30421699 [TBL] [Abstract][Full Text] [Related]
6. Optimal management of combined dyslipidemia: what have we behind statins monotherapy? Tenenbaum A; Fisman EZ; Motro M; Adler Y Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960 [TBL] [Abstract][Full Text] [Related]
7. [Recommendations of the European Society of Cardiology and the European Atherosclerosis Society on Cardiovascular Disease Prevention and Management of Dyslipidemias. for the Diagnosis of Atherosclerosis and Dyslipidemia Treatment (2016): Basic S.G.]. Bubnova MG; Kukharchuk VV Kardiologiia; 2017 Mar; 57(3):85-89. PubMed ID: 28762942 [TBL] [Abstract][Full Text] [Related]
8. Can intensive lipid-lowering therapy improve the carotid intima-media thickness in Japanese subjects under primary prevention for cardiovascular disease?: The JART and JART extension subanalysis. Daida H; Nohara R; Hata M; Kaku K; Kawamori R; Kishimoto J; Kurabayashi M; Masuda I; Sakuma I; Yamazaki T; Yokoi H; Yoshida M; J Atheroscler Thromb; 2014; 21(7):739-54. PubMed ID: 24953046 [TBL] [Abstract][Full Text] [Related]
9. [Possibilities of clinical use of ezetimibe Otrio (JSC "AKRIKHIN", Russia) in patients with high and very high cardiovascular risk who have not reached the target values of lipid metabolism. Conclusion of the Board of experts]. Kobalava JD; Gurevich VS; Galyavich AM; Kaminnyi AI; Kashtalap VV; Mareev VY; Susekov AV; Shaposhnik II Kardiologiia; 2019 Jun; 59(5S):47-57. PubMed ID: 31221075 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy. Hunninghake DB Am J Med; 1998 Feb; 104(2A):9S-13S. PubMed ID: 9550501 [TBL] [Abstract][Full Text] [Related]
11. Comprehensive geriatric assessment in elderly and senile patients with cardiovascular diseases. Expert opinion of the Russian Association of Gerontologists and Geriatricians. Tkacheva ON; Kotovskaya YV; Runihina NK; Frolova EV; Milto AS; Aleksanyan LA; Tyukhmenev EA; Shedrina AY; Rozanov AV; Ostapenko VS; Sharashkina NV; Eruslanova KA; Esenbekova EE; Fedin MA Kardiologiia; 2021 May; 61(5):71-78. PubMed ID: 34112078 [TBL] [Abstract][Full Text] [Related]
12. Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes. Gencer B; Koskinas KC; Räber L; Karagiannis A; Nanchen D; Auer R; Carballo D; Carballo S; Klingenberg R; Heg D; Matter CM; Lüscher TF; Rodondi N; Mach F; Windecker S J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122809 [TBL] [Abstract][Full Text] [Related]
13. Lipid-lowering agents for nephrotic syndrome. Kong X; Yuan H; Fan J; Li Z; Wu T; Jiang L Cochrane Database Syst Rev; 2013 Dec; (12):CD005425. PubMed ID: 24327265 [TBL] [Abstract][Full Text] [Related]
14. Lipid management for the prevention of cardiovascular disease. Schaefer JR Curr Pharm Des; 2011; 17(9):852-60. PubMed ID: 21418030 [TBL] [Abstract][Full Text] [Related]
15. Intensive LDL-cholesterol lowering therapy and neurocognitive function. Banach M; Rizzo M; Nikolic D; Howard G; Howard V; Mikhailidis D Pharmacol Ther; 2017 Feb; 170():181-191. PubMed ID: 27865998 [TBL] [Abstract][Full Text] [Related]
17. Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial. Han BH; Sutin D; Williamson JD; Davis BR; Piller LB; Pervin H; Pressel SL; Blaum CS; JAMA Intern Med; 2017 Jul; 177(7):955-965. PubMed ID: 28531241 [TBL] [Abstract][Full Text] [Related]
18. Challenges in Oral Lipid-lowering Therapy: Position Document of the Spanish Society of Cardiology. Anguita Sánchez M; Castro Conde A; Cordero Fort A; García-Moll Marimón X; Gómez Doblas JJ; González-Juanatey JR; Lidón Corbi RM; López-Sendón JL; Mostaza Prieto J; Rodríguez Padial L Rev Esp Cardiol (Engl Ed); 2016 Nov; 69(11):1083-1087. PubMed ID: 27650859 [TBL] [Abstract][Full Text] [Related]
19. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up. Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913 [TBL] [Abstract][Full Text] [Related]